Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38556 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL16554168 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL16373577 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL8131133 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL18630281 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL770738 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL28986488 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL28854937 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL28854935 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL18492053 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2022-09-20 | — | — | US | disclosed |
| EP-3572410-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| CN-108676047-B | HCV polymerase inhibitors | 美迪维尔公司 | 2021-04-02 | — | — | CN | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-11-03 | — | — | US | disclosed |
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-05-19 | — | — | US | disclosed |
| EP-3186244-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2020-04-22 | — | — | EP | disclosed |
| US-9540411-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2017-01-10 | — | — | US | disclosed |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-9481703-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2016-11-01 | — | — | US | disclosed |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| EP-3057976-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-08-24 | — | — | EP | disclosed |
| EP-3041855-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016030335-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2016-03-03 | — | — | WO | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | CYP19A1 1393/4885EPHX1 1243/4885NAAA 4044/4885 |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | CYP19A1 2799/4885EPHX1 2709/4885NAAA 715/4885 |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | CYP19A1 1206/4885EPHX1 1237/4885NAAA 4110/4885 |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | CYP19A1 1393/4885EPHX1 1243/4885NAAA 4044/4885 |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | CYP19A1 2799/4885EPHX1 2709/4885NAAA 715/4885 |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | CYP19A1 2799/4885EPHX1 2709/4885NAAA 715/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | CYP19A1 1393/4885EPHX1 1243/4885NAAA 4044/4885 |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | CYP19A1 1393/4885EPHX1 1243/4885NAAA 4044/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | CYP19A1 1393/4885EPHX1 1243/4885NAAA 4044/4885 |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | CYP19A1 1393/4885EPHX1 1243/4885NAAA 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.